Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
KU Leuven and life sciences institute VIB officially unveiled Belgium-based drug development business Augustine Therapeutics today with €4.2m ($4.7m) in seed funding to target neuromuscular disorders such as Charcot–Marie–Tooth (CMT) disease. The money was supplied by VIB and its affiliate V-Bio Ventures venture fund, as well as KU Leuven-backed seed vehicle Gemma Frisius Fund, Flemish government-owned investment firm PMV and life sciences-focused VC firm Advent France Biotechnology. CMT is a hereditary disease characterised by progressive loss of nerve function in the muscles, and treatments are currently limited to helping the patient manage their symptoms. Augustine Therapeutics extends collaborative research from VIB-KU Leuven teams led by Ludo Van Den Bosch, Joris de Wit and Bart De Strooper.
Canada-based experiential learning platform Riipen has obtained $3.8m from investors including Arizona State University-run accelerator ScaleU and SEI Ventures, the strategic investment arm of for-profit education services provider Singularity Education. The round was…
